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ABSTRACT 
 
Accumulation of genomic mutations is the consequence of failure in DNA repair as well as 
increased exposure to endogenous/environmental mutagens. DNA repair pathways safeguard 
the human genome from such mutagens, and thereby suppress the multi-step process of 
carcinogenesis. DNA repair pathways that protect the genome from ROS (reactive oxygen 
species)-induced lesions are attractive anti-cancer targets, as their inhibition may render 
combinatorial sensitization of tumor cells to both DNA damage and oxidative stresses, known 
as non-oncogenic addictions of cancer. The aim of this thesis was to validate such DNA repair 
factors as anti-cancer targets and to develop their inhibitors for potential therapeutic 
applications. 
In paper I, we assessed the addiction of cancer cells to MTH1, a nudix hydrolase eliminating 
oxidized purine nucleotides from the dNTP pool. MTH1 depletion resulted in exclusive 
accumulation of 8-oxo-dG lesions and cellular toxicity in transformed cells. MTH1 
suppression, impaired tumor growth in the xenografts of SW480 cells. We developed potent 
MTH1 inhibitors (TH278 and TH588), which exhibited target engagement and selective 
toxicity in transformed cells. Treatment with MTH1 inhibitors caused increased 8-oxo-dG 
levels in cancer cells, and inhibited the growth of xenografts in vivo. Taken together,  our 
findings revealed the dependency of tumors to MTH1 that can be targeted for cancer therapy. 
The study in paper II aimed to explore functional cooperation between MTH1 and MUTYH, a 
DNA glycosylase that removes deoxyadenines paired with 8-oxo-dG. Using stable cell lines 
expressing inducible shRNA constructs, we showed that combined depletion of MTH1 and 
MUTYH was more toxic to cells compared to individual knock-downs. In addition, 
overexpression of nuclear MUTYH could attenuate cell death induced by loss of MTH1. 
Collectively, this study provided supportive evidence for a protective role of MUTYH. 
In paper III, we described TH5487 as a novel selective inhibitor of OGG1, a DNA glycosylase 
that excises 8-oxo-dG opposite deoxycytidine. TH5487 inhibited binding of OGG1 to its 
substrate and increased thermal stability of the purified protein through interactions with 
residues in the active site. Moreover, TH5487 engaged with its intended target, increased  
8-oxo-dG level, and impaired recruitment of OGG1 to the damage site in cells. Treatment with 
TH5487 resulted in prolonged S phase, which was similar to the effect of OGG1 depletion 
using shRNAs. In addition, non-transformed cells could tolerate TH5487 treatment while 
cancer cells were more sensitive. In sum, this study highlighted the phenotypic lethality of 
OGG1 inhibition with tumors, by introducing TH5487 as a cell-active OGG1 inhibitor. 
Overall, our results increased the knowledge about dependency of cancer cells to DNA repair 
pathways of ROS-induced lesions that can be employed for the development of promising 
anti-tumor therapies.  
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1 INTRODUCTION 
 
1.1 DNA Damage 
It takes many years for cancer to develop in the human body through a multistep process in 
which mutations in genomic DNA are considered as an underlying cause [1-3]. Human cells 
gain growth advantage by acquiring certain driver mutations that result in oncogenic 
transformation and are positively selected during tumorigenesis. In contrast, passenger 
mutations do not necessarily bring survival benefits to cells but happened to exist in an ancestor 
of the cancer cells [3]. Spontaneous mutations are the outcome of multiple mutational processes 
that include exogenous/endogenous DNA damages and insufficient DNA repair, generating a 
pattern of mutations on the genome, termed mutational signatures [4].  
 
1.1.1 Endogenous Mutagens  
Endogenous and environmental mutagens render DNA damage which can be remained in the 
genome unless they get repaired (Figure 1) [5]. Spontaneous depurination/depyrimidination 
reactions frequently occur at a daily rate of 104 bases per cell [6, 7].  Natural deamination of  
5-methylcytosine at CpG sites often results in mutations observed in various cancers [8]. 
Conversion of cytosine to uracil, reported in several cancers, is a deamination reaction 
mediated by the enzymes termed AICDA (activation induced cytosine deaminase) and 
APOBEC (Apolipoprotein B mRNA editing enzyme catalytic polypeptide) [9, 10]. On top of 
these, genomic DNA is subjected to constant attack by endogenous free radicals including ROS 
(reactive oxygen species) and RNS (reactive nitrogen species). Cellular aerobic respiration, 
programmed cell death and inflammatory responses contribute to ROS generation as a  
by-product [11]. Exposure of DNA to such reactive species create more than 30 different 
oxidized lesions [12]. Among all, 8-oxodG (8-oxo-2’-deoxyguanosine) is thought to be the 
most studied oxidized lesion which is able to pair with dA leading to G:C>>T:A mutation [13-
15].  
 
1.1.2 Exogenous Mutagens 
In addition, DNA is vulnerable to exogenous mutagens of both physical and chemical types. 
UV (Ultraviolet) radiation can covalently link two adjacent pyrimidine nucleotides creating  
(6-4) PPs (6-4 pyrimidine photoproducts) and CPDs (cyclobutane pyrimidine dimers) [16, 17]. 
Accordingly, TT.AA>>CC.GG transversions have been reported in cancers originated from 
tissues exposed to UV [18]. On the other hand, ionizing radiation (IR) not only triggers ROS 
generation in cells by ionization of water molecules but also increases ROS release from 
biological sources in irradiated cells. Moreover, IR causes direct DNA damage by inducing 
formation of SSBs (single-strand breaks) as well as DSBs (double-strand breaks) [19-22]. 
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Chemical carcinogens can induce mutations by either intercalation (e.g. proflavine and 
ethidium bromide) or covalent attachment to DNA [23]. For instance, TMZ (temozolomide), 
used for malignant glioma treatment, is an alkylating agent that mainly induces O6meG  
(O6-methylguanine) formation, leading to C.G >>T.A transitions [24-26]. The tobacco 
mutagen benzo[a]pyrene undergoes epoxidation reactions by cytochromes ultimately 
producing an extremely reactive electrophilic carcinogen which causes G.C>>T.A 
transversions. Thus, tobacco smoking can increase the risk of several human cancers by 
escalating somatic mutation rates [27-30]. Overall, the prevention of mutations by DNA repair 
pathways highlights their pivotal role to avoid tumor development (Figure 2). 
 
 
 
 
Figure 1: Different types of DNA damage. Endogenous and exogenous DNA damaging agents constantly attack 
DNA, modifying the genome in different ways. Exogenous sources of DNA damage include depurination, 
deamination, and oxidation. Environmental mutagens such as chemical agents, ionizing radiation, and UV can 
induce various DNA damages. OG: 8-oxo-dG. See text for details. Figure adapted from reference [4], printed with 
permission from Nature Publishing Group. 
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1.2  Pathways that Safeguard Genomic Integrity  
1.2.1 Direct Repair and Mismatch Repair 
Human cells have evolved various pathways to prevent accumulation of DNA damage 
introduced by either endogenous or environmental carcinogens. For instance, O6meG 
generated by TMZ can be directly repaired by MGMT (O6-methylguanine DNA methyl 
transferase), which transfers the methyl group to its own cysteine residue [31] . MGMT 
promoter hyper-methylation is now used as a predictive marker for survival in glioblastoma 
[32]. In a more complex manner, MMR (mismatch repair) factors scan DNA immediately after 
replication to detect incorrect nucleotides incorporated into the nascent strand. Using MMR, 
cells can reduce the errors of replicative DNA POLs (polymerases) by 100 times to 1 in 10-9 
bases replicated [33]. Therefore, a significant rise in the spontaneous mutation rate occurs in 
MMR defective cells [34-36]. In MMR, the misincorporated nucleotide is recognized by  
MutS alpha or MutS beta which consist of MSH2-MSH6 and MSH2-MSH3 heterodimers, 
respectively. The heterodimer of MLH1-PMS2 is then recruited to the site. The endonuclease 
PMS2 makes a nick near the incorrect nucleotide introducing new entry points for the 
exonuclease EXO1. The strand with mismatch is then degraded by EXO1. Finally, the gap left 
in DNA is filled by Pol δ [37]. Failed MMR results in C>T mutation at NpCpG sequences 
(Signature 6) which largely contributes to substitutions and small indels (insertion/deletions), 
known as microsatellite instability. In addition, defects in MMR are considered as a very early 
somatic event in colorectal tumorigenesis [18, 38-40].  
 
1.2.2 Base Excision Repair 
Simple base modifications can also be corrected by BER (base excision repair) which facilitates 
elimination and replacement of a single base residue. BER has various substrates including 
DNA lesions caused by ROS, methylation, deamination and hydrolytic reactions [41].  
A damaged base, for example 8-oxo-dG paired opposite dC (8-oxo-dG:dC) is detected and 
excised by a specific DNA glycosylase; OGG1 (8-oxoguanine DNA glycosylase). Hydrolysis 
of the N-glycosylic bond leaves an AP (apurinic/apyrimidinic) site, which is then incised by 
DNA APEX1 (apurinic or apyrimidinic site) lyase. DNA polymerase β (Pol β) can then remove 
the 5ʹ-dRP (deoxyribosephosphate) moiety, as it possesses the dRP lyase activity. Pol β also 
incorporates a nucleotide in the resulting gap .Finally, the DNA ligase III-XRCC1 complex 
establishes a phosphodiester bond to fix the new nucleotide in DNA (extensively reviewed in 
[41-43]). Often, the dRP moiety may itself be damaged and resistant to removal by Pol β. Here, 
replicative polymerases in complex with PCNA can be recruited to insert several nucleotides 
and remove the offending dRP-moiety by strand-displacement synthesis (long patch BER). 
Although none of the mutational signatures are associated with BER failure, an increase in 
mutation rate and predisposition to cancer has been reported as a result of defective BER  
[4, 44]. For instance, unrepaired 8-oxo-dG:dC can lead to a G:C >> T:A mutation which is 
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avoided by OGG1 activity [45]. Furthermore, loss of OGG1 function predisposes to lung 
cancer [46-52].  
 
1.2.3 Nucleotide Excision Repair 
NER (nucleotide excision repair) can remove various DNA lesions, as it detects the bulky DNA 
lesions that distort the DNA helix. Substrates include bulky adducts caused by benzo[a]pyrene 
and UV radiation (that is, CPDs and (6–4) PPs), among others (reviewed in [53, 54]). Substrate 
recognition by NER is achieved through either GG-NER (global genome NER) or TC-NER 
(transcription-coupled NER). In GG-NER, the XPC (Xeroderma pigmentosum group  
C-complementing protein)-RAD23B complex constantly evaluates DNA integrity for various 
helix-distorting adducts, and UV–DDB (UV radiation–DNA damage-binding protein) 
facilitates the detection of lesions [53, 55-57]. On the other hand, in TC-NER, RNA Pol II 
(RNA polymerase II) stalls when it collides with a bulky lesion, indirectly facilitating DNA 
damage recognition. The DNA lesion then becomes accessible for repair when the CSB 
(Cockayne syndrome protein CSB)-CSA (Cockayne syndrome WD repeat protein CSA) 
complex binds to the halted RNA Pol II [53, 58-60]. After DNA lesion detection in both sub-
pathways, the TFIIH (transcription initiation factor IIH) complex, which includes XPA, XPB, 
and XPD, is recruited to the bulky damage. One incision is then created by the XPF–ERCC1 
endonuclease 5′ to the lesion and another cut is made by XPG 3′ to the damage, releasing a 
fragment of around 30 nucleotides [53]. The gap filling step is carried out by Pol δ, Pol ε, or 
Pol κ using the complementary strand as a template; and finally DNA ligases completes the 
NER process by ligating the newly synthesized fragment into the continuous strand  
[53, 61-65]. Nonfunctional GG-NER causes accumulation of adducts in the genome. The error-
prone POLs may bypass such lesions to ensure cell survival that comes at the cost of higher 
mutation rate [53]. Therefore, patients with the xeroderma pigmentosum disorder, who carry 
mutations in GG-NER, are highly susceptible to UV-induced skin and mucous membrane 
cancers [66]. In addition, defective TC-NER is associated with mutational signature 7 and 
signature 4, observed predominantly in UV-induced skin cancer and tobacco smoking induced 
lung cancer, respectively. As a result, both signatures show strong transcriptional strand-bias 
[4, 18, 27]. 
 
1.2.4 Non-homologous End-joining Repair 
Although IR is able to create DSBs, most of the endogenous DSBs in cells are generated by 
collision of DNA replication forks with unrepaired lesions, that results in replication fork 
collapse [67, 68]. DSBs are principally handled by two different repair pathways: NHEJ  
(non-homologous end-joining) and HR (homologous recombination). In NHEJ, DNA ends at 
DSBs are rapidly protected from exonucleases and held in close proximity by the Ku70-Ku80 
heterodimer [69, 70]. End-joining is then mediated by involvement of DNA-PKcs  
(DNA-dependent protein kinase catalytic subunit), artemis and Pol λ [71, 72]. Finally, the 
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Ligase IV-XRCC4 complex ligates the damaged DNA strands [73-75]. The activity of NHEJ 
is independent of the cell cycle phases whereas HR only takes place after DNA replication as 
it requires sister chromatids as repair templates. Contrary to general expectations, NHEJ 
to be an accurate  is foundand  ,phase cells-2in Grepair the first choice for DSBs  appears as
process due to limited end-processing and fast kinetics [76-78]. However, if the DSB yields 
ends that cannot be ligated directly by NHEJ, especially in the G1 phase where HR is not an 
option, re-joining will be mediated by microhomology. This process involves extensive  
end-trimming that results in a slower error-prone pathway called MMEJ (micro-homology 
mediated end-joining) [79-83]. During immunoglobulin gene rearrangement in B-cells, for 
generation of primary antibody repertoire, as well as T-cell receptor generation, DSB 
formationis programmed under physiological conditions which are repaired by MMEJ. Here, 
the re-joining process is mediated by RAG1 (V(D)J recombination-activating protein 1) and 
RAG2 [84-86]. Diversification of the primary antibody repertoire by immunoglobulin class 
switching is also facilitated through MMEJ initiated by AICDA [87]. Therefore, defects in 
NHEJ causes severe immunodeficiency associated with increased radiation sensitivity [88, 89]. 
 
1.2.5 Homologous Recombination Repair 
Although HR is initiated by end-trimming like MMEJ, it is an error-free process where 
duplicated sister chromatids act as a template for DNA synthesis. During HR, the DSB is first 
detected by the MRN (MRE11-RAD50-NBS1) complex. End resection is then performed by 
DNA nucleases and helicase such as EXO1, CtIP (CtBP (C-terminal-binding protein)-
interacting protein) and BLM (Bloom syndrome protein), resulting in formation of  
3'-overhangs. RPA (replication protein A) protects the overhangs, and it is later displaced by 
RAD51. The replacement step is mediated by the BRCA1 (breast cancer type 1 susceptibility 
protein)-PALB2 (partner and localizer of BRCA2)-BRCA2 complex. RAD51 forms 
nucleoprotein filaments and invades the complementary DNA template. The invading strand 
primes news DNA synthesis and forms a structure named D-loop (displacement loop).  
After branch migration and DNA synthesis, resolution of Holliday junction intermediates 
(crossover recombinants) leads to accurate repair (extensively reviewed in [68, 90, 91]). 
Inherited predisposition to breast and ovarian cancer were found in females carrying mutations 
in BRCA1 and BRCA2 [92-94]. Moreover, inactivating germline mutations in RAD51C, which 
encodes RAD51, have been associated with concurrent breast and ovarian tumors [95]. 
Accordingly, signature 3, which includes large insertions and deletions, has been detected in 
breast and ovarian tumors with germline and somatic BRCA1 and BRCA2 mutations [18].  
 
1.2.6 Replication Fidelity 
Nucleotide selectivity and proofreading by replicative DNA POLs (i.e. Pol α, δ and ε), as well 
as post-replicative MMR are crucial factors determining the fidelity of replication [96]. Such 
DNA POLs are highly selective to ensure that new nucleotides are correctly incorporated into 
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the nascent strand and accurately paired with their complements on the template strand. 
However, DNA POLs do make errors with the rate of one in every 10,000 base pairs [97]. 
Considering the human genome size (~3 × 109 nucleotides), this small mutation rate can lead 
to 105 mistakes per division. However, replicative DNA POLs reduce the number of incorrectly 
incorporated nucleotides by approximately 100-fold using their 3′-exonuclease proofreading 
activity [98]. In addition, shortly after replication MMR removes the mismatches and improves 
replication fidelity by about 100- to 1,000-fold [96]. Thus, the mutation rate is estimated to be 
less than one error for every billion base pairs duplicated during DNA replication [99]. 
Active site mutation in Pol γ (Y955C) reduces the polymerase nucleotide selectivity by two-
fold, increases mutations in mtDNA (mitochondrial DNA), and consequently causes 
progression of external ophthalmoplegia [100-102]. In addition, somatic and germline 
mutations in Pol ε impairing the proofreading activity, cause predisposition to colorectal and 
endometrial carcinomas with functional MMR [103-105]. These mutations in Pol ε are the 
underlying cause of the 'ultramutation' phenotype and associated with signature 10 [18, 106]. 
 
1.2.7 Preventive Repair 
Other factors that contributes to replication fidelity are balance and purity of the intracellular 
dNTP (deoxynucleoside triphosphate) pool [107]. Oncogene activation (e.g. cycline E 
overexpression) enforces cell proliferation that leads to insufficiency in dNTP levels. This,  
in turn, can cause DNA replication stress and genome instability in the early onset of 
tumorigenesis. Such DNA perturbations were shown to be prevented by exogenously 
supplying nucleosides or expressing c-myc, which is a TF (transcription factor) that increases 
nucleotide biosynthesis [108].  In addition, it has been shown that the dNTP pool is much more 
vulnerable to damage by modifying reagents than their counterparts in the DNA duplex  
[109-111]. Accordingly, impurities in the dNTP pool can cause replication errors and 
mutations. For example, slight amounts of 8-oxodGTP in the mitochondrial dNTP pools are 
sufficient to negatively affect the fidelity of Pol γ, leading to A:T >> C:G transversions [112]. 
Therefore, cells have evolved a preventive DNA repair mechanisms by which sanitizing 
enzymes prevent misincorporation of noncanonical or damaged nucleotides into DNA [113]. 
For instance, ITPA (Inosine triphosphate pyrophosphatase) removes noncanonical purine 
nucleotides form the pool and contributes to the maintenance of genome stability [102, 114]. 
Moreover, MTH1 (MutT Homolog 1) displays strong 8-oxo-dGTPase activity which plays a 
significant role in sanitation of the dNTP pool from oxidized purine nucleotides [115]. MTH1 
overexpression suppresses DNA damages induced by the oncogene H-RAS and significantly 
minimizes the spontaneous mutation rates in cells with malfunctioned MMR, indicating the 
role of MTH1 in mutation avoidance [116, 117]. 
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1.2.8 Translesion Synthesis 
If DNA damage remains unrepaired prior to DNA replication, which often causes replication 
fork collapse, they will be bypassed by TLS (translesion synthesis) POLs to enhance cell 
survival. TLS is mediated mainly by the low-fidelity Y- family POLs, including Pol η, Pol κ, 
Pol ι, and REV1, which lack exonuclease activity. In fact, TLS allows damage to be tolerated 
until they can be later removed by DNA repair system, thus allowing DNA replication to be 
completed. TLS is initiated by stalling of the replicative DNA POLs at DNA lesions, followed 
by recruitment of a TLS polymeraseto bypass the damage by incorporating nucleotides 
opposite the lesion. The replication machinery then switches the TLS polymerase back to the 
error-free replicative POLs [118]. Accordingly, Pol η activity during somatic hypermutation 
has been associated with Signature 9 found in in CLL (chronic lymphocytic leukemia) and 
malignant B-cell lymphomas [18, 119].  
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Figure 2: Pathways for maintenance of the genome integrity. a) Direct reversal of methylated lesions is carried 
out by direct repair pathway. b) Preventive repair does not permit incorporation of modified nucleotides into DNA. 
c) Base excision repair deals with simple base modifications. d) Mismatch repair recognizes and removes 
mispaired nucleotides. e) Bulky adducts and UV-induced lesions are fixed by nucleotide excision repair. 
f) No-homologues end-joining repairs double-strand brakes throughout the cell cycle. g) Homologous 
recombination uses the sister chromatids as template to repair double-strand brakes. OG: 8-oxo-dG,  
MG: O6mG. See text for details. Figure adapted from reference [4], printed with permission from Nature 
Publishing Group.  
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1.3  Repair of ROS Induced DNA Damage: Bringing 
 8-Oxod-G into Focus 
As discussed above, endogenous or exogenous ROS can induce a wide variety of damage to 
both DNA and its precursors, which are carcinogenic if not eliminated by repair pathways 
(reviewed extensively in [12]). The most prevalent and thoroughly examined oxidative DNA 
lesion is thought to be 8-oxo-dG which is estimated to reach 105 bases in genomic DNA per 
cell [13-15]. Perhaps, its abundance in the genome is due to the fact that guanine, compared to 
other bases, has the lowest oxidation potential which makes it the easiest nucleotide to get 
oxidized by ROS [13]. To restrict 8-oxo-dG accumulation in the genome, cells are principally 
armed with three complementary repair pathways for this simple base modification: preventive 
repair (i.e. MTH1), BER, and MMR (Figure 3).   
 
1.3.1  Preventive repair: MTH1 
MTH1, also known as nudix hydrolase 1 (NUDT1), is an antimutagenic enzyme  
that eliminates oxidized nucleotides from the dNTP pool by hydrolysis of 8-oxo-dGTP,  
8-oxo-dATP and 2-OH-dATP [120, 121]. MTH1 belongs to the nudix (nucleoside diphosphate 
linked to another moiety x, NDP-X) hydrolase superfamily including a number of enzymes that 
catalyze the following reaction: NDP-X  NMP + P-X. The nudix enzymes share a common 
23-amino acid motif called the nudix box (GXXXXXEXXXXXXXREUXEEXGU), where U 
can be valine, leucine, or isoleucine, and X is any amino acid [122-125]. MTH1 activity 
prevents misincorporation of 8-oxo-dGTPs and other oxidized purine nucleotides into DNA, 
which would otherwise results in DNA damage and cellular senescence, as shown in human 
skin untransformed fibroblasts. This replicative senescence can be rescued when the cells are 
exposed to a low oxygen level [126]. Moreover, MTH1 activity appeared to be essential to 
avoid senescence, a critical step towards tumorigenesis, in RAS-transformed cells and its 
overexpression can prevent RAS associated DNA damage [116, 127, 128]. In line with these 
observations, Fouquerel et al. demonstrated that mis-insertion of 8-oxo-dGTP into telomere 
sequences upon MTH1 depletion leads to the premature stop of telomerase and induces death 
in cancer cells with shortened telomeres [129]. In addition, mice overexpressing human MTH1 
exhibited increased longevity, owing to limited age-dependent accumulation of genomic  
8-oxo-dG [130].  
From another perspective, oxidative stress and DNA damage stress are considered to be  
non-oncogene addictions of cancer cells which may not drive tumorigenesis but are required 
for survival [131]. Thus, MTH1 is expected to play a vital role in cancer cells, mediating the 
adaptation to such persistent stress conditions. Indeed, lethality due to impaired MTH1 function 
as well as MTH1 overexpression in cancer cells has been reported in several independent 
studies. Loss of MTH1 activity has been shown to be toxic in various xenograft models using 
different shRNA (short-hairpin RNA) vectors [132-134]. MTH1 suppression also prevented 
formation of tumor spheres and xenograft tumor growth of glioblastoma cells, where toxicity 
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could be enhanced by H2O2 treatment [135]. Using gRNA (guide RNA) and an artificial virus 
delivery system, the MTH1 gene was disrupted leading to growth inhibition of subcutaneous 
xenograft tumors of SKOV3 cells [136]. Besides, comparison of healthy and tumors tissues 
revealed a significant correlation between MTH1 expression and disease progression in breast 
cancer [137, 138], colorectal cancer [139], gastric cancer [140] , non-small cell lung carcinoma 
[141, 142], esophageal squamous cell carcinoma [143], renal-cell carcinoma [144], and 
multiple myeloma [145]. The MTH1 p26 isoform is a consequence of single nucleotide 
polymorphism (SNP) in exon 4, where the Val83 is replaced with Met83 [146, 147]. Although 
p26 has the same catalytic efficiency for oxidized nucleotides as other isoforms (p22, p21, and 
p18), it appeared to be less thermostable as well as less efficiently translocated into 
mitochondria [147, 148]. Consistent with these studies, Val83Met SNP in the MTH1 gene was 
shown to significantly increase predisposition to small cell lung carcinoma (SCLC) [149].  
 
1.3.2  OGG1-mediated BER 
Misinsertion of 8-oxo-dGTP opposite dC, or direct oxidation of dG (deoxyguanine) in dG:dC 
base pairs, are mutagenic because in the next round of replication a dATP can be incorporated  
opposite 8-oxo-dG, causing G:C>>T:A transversions [150]. As mentioned earlier,  
BER-dependent removal of 8-oxo-dG:dC lesions is carried out by OGG1 [151, 152]. Both 
glycosylase activity and AP lyase activity are conducted by bifunctional glycosylases that can 
cleave the DNA strand after lesion excision without involvement of APEX1. At first, it was 
suggested that Asp268 was an essential residue responsible for the bifunctionality of human 
OGG1. In this model, Asp268 promotes the nucleophilic Lys249 to form a Schiff base enzyme-
DNA covalent intermediate, which is then hydrolyzed with a water molecule to complete the 
β-elimination reaction [153, 154]. However, OGG1 was shown later to work in a 
monofunctional mode under physiological conditions. Based on this model, Asp268 initiates 
the catalysis whereas Lys249 was found to be indispensable for 8-oxo-dG recognition [155]. 
Consist with this finding, OGG1 activity has been shown to significantly increase in the 
presence of APEX1; and the dRP lyase activity of Pol β appeared to be required for 8-oxo-
dG:dC repair [156-158]. 
The human OGG1 gene resides in chromosome 3p25 and encodes two main isoforms: α-OGG1 
(Type 1a, 39 kDa) and β-OGG1 (Type 2a, 47 kDa) [151, 159, 160]. α-OGG1 is translocated to 
both mitochondria and nuclei whereas β-OGG1 is exclusively mitochondrial [160]. β-OGG1 
(also named OGG1-2a) was shown to be catalytically inactive for the repair of 8-oxo-dG:dC 
lesions [161]. However, another isoform, OGG1-1b, has recently been reported to mediate 
BER-dependent repair of such lesions in mitochondria, similar to that of the nuclear α-OGG1 
(OGG1-1a) isoform [162, 163]. During interphase, OGG1 is associated with chromatin and the 
nuclear matrix while it is co-localized to condensed chromosomes in mitosis [164]. Particularly 
during S-phase, OGG1 was found in nucleoli [165]. Following treatment with potassium 
bromate (KBrO3) which induces 8-oxo-dG formation [146], OGG1 was preferentially recruited 
to euchromatic domains and co-localized with RNA polymerase II [166].  
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Enhanced expression of OGG1 in the nucleus and mitochondria protects DNA and 
consequently improves cell survival upon exposure to oxidative damage. However,  
over-expression of R229Q OGG1 mutant failed to exhibit such effects [167]. In fact, although 
R229Q mutation does not affect the catalytic activity of OGG1, it renders it thermolabile at 
physiological temperature [168]. In addition, mitochondrial targeted over-expression of  
α-OGG1 in the PyMT transgenic mouse model of mammary tumorigenesis resulted in 
decreased mtDNA damage, improved mitochondrial function, and attenuated breast cancer 
progression and lung metastasis [169]. Deletion at the OGG1 locus or inactivating mutations, 
with the Ser326Cys polymorphism being the most frequent, have been associated with 
increased risk of  cancer in lung squamous cells [46, 48-52], kidney [52, 170-172], oropharynx 
[173], esophagus [174], and stomach  [175]. It has been found that the Ser326Cys OGG1 has 
almost equal catalytic activity to the WT (wild type) protein for 8-oxo-dG:dC excision  
[176-178]. However, this polymorphic OGG1 is excluded from the nucleoli where the WT 
protein preferentially resides during S-phase. In contrast to the WT OGG1, the Ser326Cys 
mutant protein displayed defective associations with chromatin as well as nuclear matrix.  
The disrupted localization of Ser326Cys OGG1 was suggested to be the consequence of altered 
phosphorylation at Ser326 [164, 165]. On the other hand, it has been suggested that oxidation 
of OGG1 at Cys326 can negatively affect its repair efficiency and causes dimerization of 
OGG1 which leads to anomalous DNA binding and lack of stimulation by APEX1 [179-181]. 
In addition, novel SNPs of OGG1 in 5'-UTR (5'-untranslated regions) that reduce OGG1 
expression levels have been associated with breast cancer [182]. Consistent with this 
observation, another SNP in 3'-UTR, causing lower OGG1 expression, has been linked to 
increased risk of cancer in the people with inherited BRCA1/BRCA2 mutations, exhibiting 
shortened telomeres [183-185]. 
OGG1-dependent recognition of 8-oxo-dGs in promoter regions has been reported to promote 
transcription by several TFs such as Hif-1 (hypoxia inducible factor-1), MYC, NF-κB, and 
estrogen receptor. [186-190]. Particularly in estrogen-induced transcription, demethylation of 
H3 lysine 9 at promoter sites is catalyzed by an epigenetic modulator enzyme called LSD1 
(lysine-specific demethylase 1) [191, 192]. LSD1 activity results in H2O2 production that in 
turns results 8-oxo-dG formation in the surrounding DNA strands, recruiting OGG1 [190].  
In a similar manner, LSD1-mediated recruitment of OGG1 has been found for Myc-dependent 
transcription [189]. Thus, OGG1 not only is required for repair of oxidized lesions but also 
exhibits an important role in ROS-associated transcriptional regulation (reviewed in [193]). 
 
1.3.3  MUTYH-dependent BER 
The replicative POLs can misincorporate dATP opposite the already existing 8-oxo-dG in 
template DNA, with syn conformation, to form dA:8-oxo-dG pairs [194, 195]. Such lesions, if 
left unrepaired, can lead to C:G>>A:T transversion mutations. Another DNA glycosylase 
called MUTYH (MutY homolog) initiates repair of dA:8-oxo-dG mispairs by monofunctional 
excision of the incorrectly paired adenine from the DNA strand. MUTYH is also known as 
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adenine DNA glycosylase and it has the capacity to remove both dA and 2-OH-dA when paired 
with dG or 8-oxo-dG [196-199]. In case of dA:8-oxo-dG mispairs, since  MUTYH  removes 
the undamaged base, the enzyme needs to distinguish the nascent strand from the template 
strand, otherwise activity of MUTYH on these  lesions where dA is in the template strand can 
give rise to mutations [200]. In fact, MUTYH has been shown to possess a replication-
associated function. Accordingly, MUTYH interacts with several proteins involved in DNA 
replication, co-localizes with PCNA (proliferating cell nuclear antigen), and is up-regulated 
during S-phase [201, 202]. In addition, MUTYH-dependent repair of dA:8-oxo-dG lesions was 
enhanced by DNA replication where expression of a mutant form of MUTYH lacking its 
PCNA binding motif could not increase the repair efficiency [203]. On the other hand, 
MUTYH-initiated SP-BER (short-patch BER) appeared to be futile since it only generates 
dA:8-oxo-dG mispairs [204]. Instead, it has been shown by several studies that MUTYH 
dependent repair includes a replication-coupled LP-BER (long-patch BER) pathway  
[202, 205, 206]. It has been demonstrated that Pol λ is involved in MUTYH-initiated LP-BER 
where it can accurately incorporate dCTP opposite 8-oxo-dG [207, 208]. RPA and PCNA 
collaboratively function as a molecular switch to activate Pol λ dependent LP-BER and 
suppress Pol β activity [209]. The 8-oxo-dG apposite the AP site, which is generated by 
MUTYH activity, can be recognized by OGG1. However, it was shown that murine Mutyh can 
inhibit Ogg1 in this context to prevent mutation [210]. In sum, MUTYH removes adenine from 
dA:8-oxo-dG mispairs, where dA is in the newly synthesized strand, and represses OGG1 
activity. Then, the APEX1 makes an incision at the AP site. Afterwards, RPA and PCNA 
promotes Pol λ to incorporate dCTP and extend the primer by one additional nucleotide, while 
Pol β activity is inhibited. The one-nucleotide 5′ overhang is then processed by FEN1  
(flap endonuclease 1), and subsequently the DNA ligase I seals the nick. Thus, the MUTYH 
repair pathway creates substrates (i.e. dC:8-oxo-dG mispairs) for OGG1-mediated SP-BER 
where Pol β is involved [208]. 
The human MUTYH gene is mapped to chromosome 1p34.1 and encodes three main 
transcripts: α, β, and γ generated from three different exon 1 sequences. These transcripts 
generate at least 9 different isoforms of MUTYH protein among which type 1 and type 2 are 
the major mitochondrial (60 kDa) and nuclear (57 kDa) variants, respectively [196, 198, 211] 
[159, 201, 212-214]. Since the mitochondrial targeting sequence is located at the N-terminus 
of MUTYH, missense mutations in this region can disrupt the protein localization. 
Accordingly, Pro18Leu and Gly25Asp MUTYH variants have been associated with increased 
susceptibility to colorectal and gastric cancer [215, 216]. It has been shown that depletion of 
MUTYH sensitizes the cells to oxidative DNA damage [217]. Moreover, in LCLs 
(lymphoblastoid cell lines), derived from patients harboring loss of function mutations in the 
MUTYH gene, accumulated 8-oxo-dG lesions and KBrO3-induced hypermutability has been 
observed, indicating the protective role of MUTYH against oxidatively induced DNA damages 
[218, 219]. Consistent with these reports, AluYb8MUTYH SNP, insertion of a mobile element 
in the intron 15, causes substantial decrease in type 1 mitochondrial MUTYH, leading to 
increased mtDNA damages. This SNP has been associated with increase susceptibility to  
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age-related diseases as well as type 2 diabetes [220-224]. Reduced MUTYH level has also been 
reported in prostate adenocarcinoma and it is also associated with a poor prognosis in gastric 
cancer [225, 226]. 
Inherited mutation in the APC (adenomatous polyposis coli) gene is known as the underlying 
cause of an autosomal dominant disease called FAP (Familial adenomatous polyposis).  
The APC gene is also the most frequently mutated gene in sporadic colorectal cancer. 
Formation of numerous adenomatous polyps in the gastrointestinal tract is a FAP associated 
characteristic (extensively reviewed in [227-230]). Al-Tassan and coworkers identified a 
British family with multiple colorectal adenomas and carcinoma that were not carrying 
inherited inactivating mutations in the APC gene. Instead, the APC gene contained a high level 
of somatic G:C>>T:A transversions, which could be a signature of defective OGG1/MUTYH-
mediated repair. The patients appeared to harbor biallelic driving mutations in MUTYH, which 
was the cause of their predisposition to MAP (MUTYH-associated polyposis), an autosomal 
recessive disease [231-235]. Spontaneous G:C>>T:A transversions in APC or KRAS, as a result 
of failed MUTYH-dependent repair, can trigger tumorigenesis in MAP patients [235-238].  
In fact, MAP is not restricted to gastric tumors and thus increased risk of extraintestinal 
malignancies including ovarian, bladder, skin, and breast cancers has been reported in MAP 
patients [239-241]. 
Pathogenic APC mutations mostly generate a truncated protein. However, the majority of 
pathogenic MUTYH variants (>50) are missense mutations. The most prevalent missense 
mutations observed in MAP patients (~80%) are Tyr165Cys and Gly382Asp [214]. 
The MUTYH Tyr165Cys variant, in which substitution occurs at the DNA minor groove 
binding motif,  displayed severe impaired glycosylase activity and substrate binding capacity 
[242-247]. The Gly382Asp mutation is localized in the C-terminal domain of MUTYH where 
the nudix domain exists, which is critical for 8-oxodG recognition [248-250]. The MUTYH 
Gly382Asp variant showed reduced glycosylase activity and partial suppression of mutation 
frequency compared to the WT protein [242-244, 246]. Consistent with these observations, 
phenotypic effects of Gly382Asp mutation appeared to be relatively milder than that of 
Tyr165Cys variant in MAP patients [251]. 
 
1.3.4 Role of MMR and NER in 8-oxo-dG Removal 
If the POLs misinsert 8-oxo-dGTP opposite the already existing dA in DNA, the newly formed 
8-oxo-dG:dA mispair can be detected by MMR [200]. Activity of MutS alpha can be stimulated 
by binding to 8-oxo-dG:dA and 8-oxo-dG:dT lesions, but not by 8-oxo-dG:dC mispairs [252]. 
In addition, both baseline and H2O2 induced 8-oxo-dG levels were significantly higher in 
MMR-defective cells [253]. MSH2- deficient cells were also shown to be highly sensitive to 
H2O2 and methotrexate treatments [254]. Collectively, these studies indicate the important 
contribution of MMR in removal of oxidatively induced DNA damages. 
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Although 8-oxo-dG lesions are not considered as substrates for NER, TC-NER appears to have 
a regulatory role on the BER-mediated repair of simple oxidative DNA damage [255].  
CSB-deficient cells showed a considerably reduced capacity for repair of 8-oxo-dG lesions 
owing to decreased expression of OGG1, suggesting a regulatory function on OGG1-
dependent repair [256-259]. In fact, CSB is recruited to oxidative DNA lesions but it does not 
initiate NER [260].  
 
1.3.5 Mouse Models of the 8-oxo-dG Repair Pathways 
Mth1 deficiency did not lead to elevated genomic 8-oxo-dGs [261]. However, the Mth1-KO 
(knock-out) mice exhibited a significantly higher number of spontaneous tumors in the lung, 
liver and stomach in comparison with their WT littermates [262, 263]. On the other hand, 
overexpression of human MTH1 in mice prevented age-associated accumulation of genomic 
8-oxo-dGs and improved longevity compared to WT mice [130]. 
Although accumulated nuclear 8-oxo-dGs and slightly higher mutation rate were observed in 
the liver of Ogg1−/− mice, they did not exhibit elevated carcinogenesis [264, 265]. This indicates 
that back-up repair pathways could contribute to avoid tumorigenesis in the absence of Ogg1 
activity. In addition, it confirms that Ogg1-dependent repair is not necessarily coupled to 
replication since liver is a non-proliferative tissue. In another study, Ogg1 deficiency resulted 
in remarkably higher 8-oxo-dG accumulations as well as mutagenicity in the liver of the KO 
animals compared to their WT counterparts. However, similar to the pervious study, these 
animals did not show elevated tumor formation [266]. When these animals were exposed to 
KBrO3, a substantial increase of 8-oxo-dG lesions were observed in both liver and kidney, 
without any escalated tumorigenesis [267-269]. Contrary to these studies, Sakumi et al. created 
Ogg1−/− mice in which 8-oxo-dG content of their genome was considerably high, leading to 
increased spontaneous tumors in lung [261]. DKO (double knock-out) of Ogg1/Mth1 in these 
mice led to a moderate increase in genomic 8-oxo-dG lesions while suppressed tumor 
formation in the lung, suggesting that Mth1 deficiency might trigger tumor cell death under 
these conditions.  
Similar to Ogg1, age-dependent 8-oxo-dG accumulation appeared only in the liver of Mutyh-
null mice. However, concurrent deletion of Ogg1 and Mutyh caused a significantly greater level 
of 8-oxo-dG lesions in lung and small intestine, in addition to liver [270]. Moreover, mice with 
combined deficiency in Ogg1 and Mutyh, were more prone to development of lymphomas, 
lung and ovarian tumors compared to WT mice [271]. In an independent study, Sakamoto and 
colleagues showed increased intestinal tumorigenesis in Mutyh-KO mice that could be 
enhanced by KBrO3 treatment [272]. Simultaneous deletion of Mth1, Ogg1, and Mutyh could 
dramatically increase the mutation rate where somatic and germ line mutations appeared to be 
G:C >> T:A transversions. Such TKO (triple knock-out) mice developed various types of 
tumors in several organs and had a shorter lifespan [273].  
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Msh2-deficient mice displayed a strong mutator phenotype and were considerably predisposed 
to lymphoma [274, 275]. Deletion of Mth1 in Msh2−/− background led to a remarkable increase 
in spontaneous G:C>>T:A transversions compared to Msh2-null mice [276]. Furthermore, 
when both Msh2 and Mutyh were deleted, higher levels of 8-oxo-dG lesions were observed in 
several tissues compared to WT and single KO mice. However, these DKO mice displayed a 
strong delay in lymphoma development, suggesting a protective role for MUTYH against 
MSH2-associated tumorigenesis [277]. On the other hand, KO of the Csb gene did not affect 
the level of 8-oxo-dG lesions in the liver of mice. However, concurrent inactivation of Csb and 
Ogg1 led to higher accumulation of oxidative DNA damage in the liver, kidney and spleen 
compared to single KO mice, indicating an alternative role for CSB protein [278].  
 
Figure 3. Main pathways responsible for the repair of 8-oxo-dG. MTH1 eliminates  
8-oxo-dGTP from the dNTP pool. OGG1 excises the 8-oxo-dG when paired with dC. MUTYH recognizes 
 dA:8-oxo-dG mispairs and removes the dA from the nascent strand. MMR (MutSα) detects dA:8-oxo-dG mispairs 
and removes the 8-oxo-dG from the newly synthesized strand. The nascent strand and the template strand are 
shown in red and blue, respectively. See text for details. Figure reprinted from paper II, with permission from 
Nature Publishing Group. 
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1.4 Anti-Cancer Targets within DNA Repair Pathways  
1.4.1 Oncogene Addictions 
During carcinogenesis, cells gain a common set of features referred to as the hallmarks of 
cancer. Such properties are acquired through a multi-step process that includes gain-of-function 
mutations/ overexpression of oncogenes along with inactivating mutations/deletion of tumor 
suppressors [131, 279]. These genetic alterations are considered as driver mutations which lead 
tumor development [280]. Therefore, targeting these OA (oncogene addictions) is an 
established strategy to treat cancer (reviewed in [281]). For instance, inhibitors of EGFR 
(epidermal growth factor receptor) are developed to disturb sustainable proliferative signaling, 
which is a known hallmark of cancer cells. Overexpression of EGFR is reported in at least 62% 
of NSCLC (non-small-cell lung cancer) and it its expression confers an adverse prognosis  
[282-286]. Elevated level of EGFR can constantly trigger the SOS-Ras-Raf-MAPK cascade 
that rewires the signaling pathway to promote cell proliferation [287]. Inhibitors of the tyrosine 
kinase activity of EGFR, such as gefitinib and erlotinib, are clinically used for treatment of 
NSCLC patients with activating EGFR mutations [288-293]. These drugs compete with ATP 
molecules for binding to the EGFR active site [294, 295]. 
 
1.4.2 Non-oncogene Addictions 
On the other hand, cancer cells display additional common properties that are not responsible 
for the tumorigenic process but are critical for enhancing their cellular adaptations and viability. 
These NOA (non-oncogene addictions) include various stress phenotypes of cancers such as 
DNA damage stress, oxidative stress, and mitotic stress, among others. In other words, the 
genes or pathways contributing to NOA are required to favor cancer stress phenotypes but are 
not essential for survival in normal cells. Accordingly, application of additional stress to tumor 
cells can selectively kill them while exerting minor effects on normal cells. In addition, 
sensitization of cancer cell to their existing stress phenotypes could be another approach to 
trigger death exclusively in tumors [296]. To achieve stress sensitization, the pathways should 
be targeted whose inhibition renders synthetic lethality with genotype or phenotype of tumors 
[131, 296, 297]. Based on these principles, several targets within DNA repair pathways have 
been identified [298, 299] (Figure 4). 
 
1.4.3 Stress Overload 
Approximately. half of cancer patients are currently treated with RT (radiotherapy) [300]. In 
fact, this well-established treatment overloads cells with DNA damage stress and oxidative 
stress. However, since tumor cells exhibit elevated stress phenotypes, they are more vulnerable 
to IR treatment. It has been shown that inhibiting certain proteins in DNA repair pathways can 
make cancer cells sensitive to IR and reduce its toxic effects on normal cells. For instance, 
DNA-PK defective cells were found to be highly sensitive to IR [301-304]. Several attempts 
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have been made to develop small molecules inhibiting the kinase activity of DNA-PKcs. 
NU7026 and NU7441 are potent and selective inhibitors of DNA-PKcs which can considerably 
sensitize the cells to IR as well as DSB inducing agents (e.g. topoisomerase inhibitors)  
[305-309]. However, due to poor pharmacokinetic parameters, their clinical applications are 
restricted [308, 310]. Currently, MSC2490484A is being assessed in phase I clinical trials, 
either as monotherapy or in combination with RT, for the treatment of advanced solid tumors 
or CLL (chronic lymphocytic leukemia) (ClinicalTrials.gov Identifier: NCT02316197, 
NCT02516813). Furthermore, CC-122 and CC-115 (dual inhibitors of DNA-PK and mTOR) 
are also being investigated in phase I clinical trials for treatment of hematologic malignancies 
or advanced solid tumors (NCT01421524, NCT01353625). 
Frontline chemotherapeutic alkylating agents can also be considered as examples of the stress 
overload strategy for cancer treatment (reviewed in reference [26]). For instance, FDA (Food 
and Drug Administration) granted accelerated approval for the TMZ treatment of patients with 
resistant anaplastic astrocytoma, a rare malignant brain tumor, in 1999. TMZ treatment was 
combined with RT to improve the efficacy in tumors, leading to a full FDA approval for 
treatment of GBM (glioblastoma multiform) in 2005 [311]. In addition, patients with 
inactivated MGMT appeared to benefit from TMZ treatment [312, 313]. Thus, blocking the 
direct repair pathway using small molecule inhibitors of MGMT can further sensitize tumor 
cells to alkylating agents [314-316]. Many of the chemotherapeutic drugs as well as RT, create 
DNA damage that BER contributes to their repair process. Therefore, combination of BER 
inhibitors with DNA damaging agents is another example of the stress sensitization approach 
[317, 318].  TRC102 is the most advanced inhibitor of APEX1 which is currently in phase I 
clinical trials. Combination of TMZ with TRC102 is being evaluated for treatment of relapsed 
solid tumors and lymphomas (NCT01851369). In another trial, TRC102 has been combined 
with pemetrexed in patients with advanced solid tumors [319].  
 
1.4.4 Stress Sensitization and Synthetic Lethality  
Exploiting the synthetic lethality concept for tumor treatment can be considered as the stress 
sensitization approach where rational targeting of pathways synergizes with the cancer 
genotype or phenotype to induce cell death. For instance, BRCA1/2-inactivated cells were 
reported to be highly addicted to the activity of an enzyme called PARP1 (Poly (ADP-ribose) 
polymerase-1) [320]. Inhibition, PARP1 activity has been shown to be synthetically lethal with 
BRCA deficiency, which is found in inherited breast and ovarian cancers [92-94, 321-323]. 
PARP1 binds to SSBs and promotes their efficient repair [324]. Strom et al. suggested a model 
for this synthetic lethality in which the PARP1 inhibitor traps the protein onto SSB 
intermediates, creating an obstacle to replication fork progression that would require HR to 
bypass [325]. Alternatively, it is shown that replication restart at stalled forks is dependent on 
HR and PARP1. Therefore, preventing PARP1 activity in a BRCA-null background causes 
inefficiency in replication restart [296, 326-328].  
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Olaparib (AZD2281) is a potent PARP1 inhibitor that was evaluated, for the first time in a 
phase I study, as a single agent in tumors from BRCA mutation carriers [329]. In this study, 
antitumor activity of olaparib was observed in patients with inherited BRCA-mutated breast, 
ovarian, or prostate tumors [329]. The efficacy of olaparib was confirmed in a  
proof-of-concept phase II trial where approximately one-third of the BRCA-defective patients 
responded to the therapy without severe toxicities [330, 331]. Finally, olaparib received FDA 
approval in 2014 based on a clinical trial in which good responses were observed across various 
tumor types associated with inherited BRCA mutations [332]. The successful story of olaparib 
prompted the development of several PARP1 inhibitors that are currently in clinical trials, such 
as rucaparib (AG014688) and veliparib (ABT-888) (extensively reviewed in reference [333]). 
Since PARP1 contributes to the repair of SSBs, applications of PARP1 inhibitors are not 
restricted to BRCA deficiency and can be used for chemopotentiation of DNA damaging agents 
[333-335]. In addition, PARP1 inhibitors would be considered as radiosensitizers 
(NCT01264432, NCT01460888) [336-338].  
NOA of ATM-(ataxia telangiectasia mutated)deficient cells to DNA-PK activity has revealed 
another synthetic lethality interaction [339]. ATM is a kinase that initiates the DDR (DNA 
damage response) upon formation of DSBs and mediates their HR-dependent repair [340-344]. 
Thus, deficiency in ATM-mediated DDR attenuates HR, leading to increased radiosensitivity 
[345]. Atm-null mice are sterile with increased incidence of lymphomas, while DNA-PKcs KD 
mice are fertile with severe immunodeficiency [346-348]. However, deleting Prkdc (the gene 
encodes DNA-PKcs) in Atm -/- background leads to early embryonic lethality [349]. 
Consistent with this, toxicity of DNA-PKcs inhibitors in ATM-defective lymphomas has been 
reported [350]. Dependency of ATM-mutated tumors on NHEJ for DSB repair accounts for 
this synthetic lethality [351]. In addition, APEX1 inhibitors can be used as monotherapy in  
HR-defective tumors due to synthetic lethal interactions with inactivating mutations in BRCA 
and ATM [352]. TRC102 is currently in clinical trials and might be assessed for synthetic lethal 
strategies. 
Regardless of the tumor genetic background, exploiting synthetic lethality with cancer 
phenotypes could be a more general therapeutic approach. For example, the inhibitors of heat 
shock protein 90 (HSP90) are able to sensitize tumors to proteotoxic stress, which is an NOA 
[353]. Here, we present targeting DNA repair pathways of oxidatively induced lesions as a 
phenotypic lethality approach for cancer therapy.  
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Figure 4. Different Therapeutic approaches for cancer treatment. Targeting oncogenic addictions is a simple 
and widely used anti-cancer strategy. However, non-oncogenic dependencies of cancer cells can be targeted by 
application of more stress or sensitization to their stress phenotypes. Rational targeting of DNA repair pathways 
can lead to synthetic lethality with the genotype or phenotype of tumors. Examples of these strategies are listed in 
the boxes, which are discussed in details in the text. EGFRi: EGFR inhibitors, TMZ: temozolomide. 
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2 AIM OF THE THESIS 
 
DNA repair proteins that maintain genomic integrity against oxidative damage pose attractive 
anti-cancer targets, as inhibiting these pathways can principally sensitize tumors to both DNA 
damage stress and oxidative stress. Accordingly, the overall aim of this thesis is to validate 
such enzymes as targets for inducing phenotypic lethality in cancer. Moreover, considerable 
efforts were made to develop novel small molecule inhibitors of MTH1 and OGG1, followed 
by evaluation of the compounds in various assays.  
In paper I, we aimed to assess MTH1 as a novel therapeutic target within DNA repair. We 
showed the NOA of cancer cells to MTH1 activity and subsequently developed a potent MTH1 
inhibitor (TH588). TH588 was validated in this study and appeared to inhibit tumor growth  
in vivo.  
The aim of paper II, as a follow-up study to paper I, was investigation of functional cooperation 
between MTH1 and MUTYH. The study tried to provide supportive evidence for a protective 
role of MUTYH in the absence of MTH1. This study revealed a toxic synergism upon 
concurrent loss of both MTH1 and MUTYH.  
In paper III, we aimed to examine the dependency of cancer cells on OGG1 activity. The second 
goal was to generate selective and potent small molecules inhibitors of OGG1. TH5487 was 
described and validated as a novel OGG1 inhibitor with selective anti-tumor effects.  
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3 METHODOLOGY 
 
3.1 Target Validation  
Target validation is a process in which a molecular target is meticulously investigated to ensure 
that the target deserves drug development. Several techniques can be exploited to validate a 
target ranging from in vitro methods to animal models. Simply, target validation can be carried 
out by depletion of the target in cells and subsequent analysis of observed phenotypes.  
Genetic techniques are used to knock down a target, such as RNAi (RNA interference) or 
CRSPR/Cas9 gene perturbation [354]. 
 
3.1.1 Silencing of Target Genes by RNA Interference  
siRNAs (small interfering RNAs) are introduced to cells by transient transfection or invading 
virus particles that contains shRNAs (small hairpin RNAs). An enzyme called Dicer mediates 
the cleavage of shRNAs, converting them into siRNAs. One strand of the resulting siRNA, 
called guide strand, triggers silencing of the target gene by binding to the RISC (RNA-induced 
silencing complex) complex, which mediates fragmentation of the complementary mRNA to 
the guide strand [355]. We suppressed expression of several target genes in our studies using 
transient transfection of siRNAs or by establishment of stable cells lines expressing lentiviral 
shRNAs (paper I: Figure 1, 2, Extended Data Figure 1; paper II: Figure 1; paper III: Figure 4, 
5). 
 
3.1.2 Assessment of Target Knock-down  
When a target is silenced by siRNAs, the efficiency of KD (knock-down) needs to be assessed 
at both mRNA and protein levels. qRT-PCR (quantitative real-time polymerase chain reaction) 
is a widely used method to analyze the efficiency of KD at mRNA level and it can also be used 
for gene expression analysis. In principle, total RNA is extracted from samples and then cDNA 
is synthesized by reverse transcription using random hexamers and oligo (dT) primers. The 
resulting cDNA sample is mixed with the qRT-PCR reaction buffer which contains SYBR 
Green, a hot-start DNA polymerase, dNTPs, and primer pairs. The design of primer pairs is a 
critical step because they should be specific to the target gene and preferentially be inefficient 
to amplify the genomic DNA contaminations. SYBR Green is a DNA stain that emits 
fluorescence more strongly when bound to double stranded DNA, and thus its signal correlates 
with the amount of DNA amplified in qRT-PCR reaction. The qRT-PCR instrument collects 
the intensity of fluorescence after each cycle and the results are normalized to multiple 
housekeeping genes. The comparison of normalized expression between control samples and 
KD-samples determines the efficiency of suppression [356]. We assessed the efficiency of KD 
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for several targets using qRT-PCR. In addition, qRT-PCR was used for gene expression 
analysis in our studies (paper I: Extended Data Figure 7, 8; paper II: Figure 1, 5) 
In addition, WB (Western blotting) can be used to evaluate the target KD at protein level. 
Briefly, after preparation of cell extract, the sample is heated to denature proteins in the 
presence of reducing agents. After electrophoresis of the sample, the proteins are transferred 
form SDS-PAGE into an adsorbent membrane. The membrane is then blocked for unspecific 
bindings and then probed with specific antibodies detecting their targets [357].  
We frequently used WB to study the efficiency of KD, change in protein levels, and cellular 
signaling such as protein phosphorylation during DDR (paper I: Figure 2, Extended Data 
Figure 1, 2, 6, 7, 8; paper II: Figure 1, 3, 4; paper III: Figure 5, 6). 
 
3.1.3 Analysis of Cell Cycle Distribution  
Depletion/inhibition of an anti-cancer target often leads to a change in normal cell cycle 
distribution of transformed cells. FC (flow cytomerty) provides robust analysis of the cell cycle 
distribution. In univariate analysis, cells are simply fixed and stained with DNA specific dyes 
such as DAPI (4′,6-diamidino-2-phenylindole), Hoechst 33342, or PI (propidium iodide).  
The DNA content frequency histograms display cell populations in G1, S and G2/M phases as 
the intensity of dye correlates with amount of DNA in each cell cycle phase of individual cells. 
In bivariate analysis, cells are pulsed with EdU (5-ethynyl-2'-deoxyuridine). The active 
replicating cells incorporate EdU into their nuclear DNA which facilitates discrimination of 
cells in S phase from others. Cells are then stained with a DNA specific dye as well as a 
clickable fluorescent marker for conjugation to EdU. The scatter plots, in which DNA content 
is plotted against EdU incorporation, display three distinct populations representing G1, S, and 
G2/M cells [358]. We analyzed the effect of silencing our molecular targets, by  
shRNA-mediated KD or compound treatment, on the cell cycle distribution using FC (paper 
II: Figure 2, 4; paper III: Figure 5). 
 
3.2 Cell Death Assays 
Cell death is examined after depletion or inhibition of a potential target to validate the 
dependency of cancer cells to the target. Since cell death may be triggered by various pathways 
such as apoptosis, necrosis, autophagy, and mitotic catastrophe, it is essential to distinguish 
such death modes and to use appropriate cell death assays [359]. 
 
3.2.1 Vital Stains and Dye Exclusion Method 
A very simple assay of cell death assessment is dye exclusion method in which a vital dye 
selectively stain dead cells by penetrating their compromised plasmas membrane. For instance, 
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Trypan blue and DAPI are vital dyes which have been used frequently in our studies [360]. 
Cellular proliferation upon depletion/inhibition of a target can be monitored using this method 
(paper III: Figure 4)  
 
3.2.2 Colony Formation Assay 
Colony formation assay, also known as clonogenic survival assay, measures the capability of 
an individual cell to grow into a colony that may consist of approximately >50 cells.  
Before or after treatment, cells are plated in appropriate densities to grow at least seven days. 
Cells are then stained with a solution containing methanol and methylene blue, and 
subsequently colonies are counted using colony counters [361]. The toxicity of MTH1 
depletion/inhibition was assessed using this method (paper I: Figure 1, 4, Extended Data Figure 
1, 5) 
 
3.2.3 Resazurin Viability Test 
The measurement of metabolism is a common way of examining cellular viability. Tetrazolium 
dyes, such as MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and 
resazurin, are absorbed by living cells and converted from colorless salts into colored 
substances. The conversion is catalyzed by mitochondrial reductases using NAD(P)H. 
Therefore, any other factor that affects this conversion can also influence the read-out in this 
assay, suggesting that the MTT test is not a stand-alone method for measuring viability [362] 
[363]. In our studies, the viability of cells were monitored using resazurin dye after treatment 
with MTH1 or OGG1 inhibitors (paper I: Extended Data Figure 5; paper III: Figure 3, 4, and 
6).  
 
3.2.4 Measurement of Caspase Activity 
Caspase proteins are well-studied factors that play central roles in programmed cell death. 
Although they appear to have additional inflammatory functions, analysis of their activity still 
remains essential for apoptosis detection [359, 364]. Measurement of cleaved/activated the 
executioner caspase-3 level is a widely used method for assessment of apoptosis induction. 
There are several decent antibodies for detecting cleaved caspase-3 which can be used in WB, 
FC or IF (immune-florescent) microscopy (paper I: Figure 2; paper II: Figure 3).  
 
3.2.5 Assessment of DNA Fragmentation (sub-G1 fraction) 
Internucleosomal DNA fragmentation by endonucleases is a well-known hallmark of cell death 
[365, 366]. Thus, as a result of DNA degradation, apoptotic cells exhibit fractional DNA 
 24 
content when stained with DNA specific dyes. Such cell population constitute a typical  
sub-G1 peak on the histograms of DNA content [367] [368]. We measured the level of sub-G1 
populations in our studies using DAPI staining (paper II: Figure 2, 4; paper III: Figure 4).  
 
3.2.6 Redistribution of Phosphatidylserine  
PS (phosphatidylserine) is normally located in the inner plasma membrane leaflet. 
Redistribution of this phospholipid to the outer leaflet occurs as an early event in apoptosis. 
Using a PS-binding protein called annexin V, it is possible to detect PS exposure during 
apoptosis [369]. When annexin V is combined with a cell impermeable DNA-binding dye such 
as DAPI or PI, it would be more convenient to distinguish apoptosis from necrosis [370, 371]. 
In paper II, apoptosis induction was detected using annexin V-DAPI staining (paper II: Figure 
3).  
 
3.3 Assessment of DNA Damage  
Since we have focused on targeting DNA repair pathways for cancer treatment, detection of 
DNA damage is critical for our studies. Generally, the methods for detecting DNA damage can 
be classified into two groups: indirect and direct detection methods. DNA damage induces 
formation of nuclear repair foci and modifications in chromatin. Therefore, monitoring these 
damage-induced consequences are considered as indirect detection methods. On the other 
hand, DNA damage can be analyzed by direct quantifications of the lesions [372].  
 
3.3.1 Detection of DSBs 
Upon induction of DSBs, repair factors are recruited to the site of damage. Several repair 
proteins, including RAD51 and 53BP1 (p53-binding protein 1), exhibit diffuse nuclear staining 
in normal conditions but they form nuclear foci upon DSBs generation. These foci can be 
detected by specific antibody staining and subsequent IF microscopy [372]. We showed 
induction of 53BP1 foci after depletion/inhibition of MTH1 using IF microscopy (paper I: 
Figure 1, 2, 3, Extended Data Figure 1, 6). Another method for indirect measurement of DSBs 
is quantification of histone H2AX phosphorylation at Ser 139 (γH2AX). Immediately after 
DSB formation, γH2AX is formed by ATM kinase activity, and thus the number of γH2AX 
foci directly correlates with the number of induced DSBs. Using antibodies against γH2AX, 
the induction of DSBs can be detected by WB, FC or IF microscopy [372]. We measured the 
γH2AX level after depletion/inhibition of OGG1 using WB analysis (paper III: Figure 5). 
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3.3.2 Live Cell Imaging  
DNA repair factors can be tagged with a fluorescent protein (e.g. GFP) and expressed in cells. 
Therefore, foci formation or recruitment of the GFP-tagged protein can be analyzed after DNA 
damage induction in live cells. FRAP (fluorescence recovery after photobleaching)  
is a technique in which a defined region of the cells expressing a GFP-tagged protein is 
bleached by laser and immediately the recovery of the GFP signal in the region is monitored. 
The recovery of the signal indicates the kinetics of diffusion for the GFP-tagged protein from 
the undamaged sites to the region [372]. Using FRAP analysis, we showed that treatment of 
cells with TH5487 can reduce the nuclear mobility of OGG1, indicating the engagement of the 
compound with OGG1 (paper III: Figure 3).  
 
3.3.3 Comet Assay  
DNA strand breaks in individual cells can be visualized by comet assay, also known as single 
cell gel electrophoresis assay. For the comet assay, cells are harvested after treatment to prepare 
single cell suspension. The cells are then embedded in a low-melting temperature agarose gel 
covering microscopic slides. Next, the cells are subjected to in-gel lysis, flowed by alkaline 
DNA unwinding and electrophoresis. Afterwards, the samples are neutralized, stained with a 
specific DNA dye (e.g. YOYO-1 and SybrGold), and finally the strand breaks are visualized 
as comet tails under a microscope. Although the comet assay is a sensitive method, technical 
variability and small sample size are considered as drawbacks of this technique [373]. We used 
a modified comet assay in our studies that is described in the next section.  
 
3.3.4 Quantification of 8-oxo-dG  
Considering the low background level of 8-oxo-dG in normal conditions, a highly sensitive 
method with minimal variability is required to quantify such lesions. Antibodies are developed 
to detect 8-oxo-dG which can be used in IF microscopy. However, these antibodies are not 
very specific and the results require a secondary assay for confirmation. Avidin appeared to 
have a capability of 8-oxo-dG recognition [374]. The Kd (μM) values for 8-oxod-G and 8-oxo-
dA were found to be approximately 117 and 24, respectively [375]. Fluorophore conjugated 
avidins can be used in IF microscopy or FC analysis [376]. Similar to the antibodies, avidin is 
not highly specific to 8-oxo-dG and avidin-based measurements were not found to be sensitive. 
Chromatographic methods such as HPLC-ECD and LC-MS/MS have been employed to 
measure 8-oxo-dG. However, these methods are troubled by spurious dG oxidation during 
sample preparation steps [377, 378]. To detect 8-oxo-dG lesions with high sensitivity and 
specificity, a modified version of comet assay has been developed where cells are treated with 
purified OGG1 after lysis [379]. The technical variability is known to be the major downside 
of this assay [373, 377]. Overall, the 8-oxo-dG detection assays require further improvements 
and standardization. In paper I1, we detected 8-oxo-dG levels using avidin-based IF 
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microscopy as well as modified comet assay (paper I: Figure 1, 4, Extended Data Figure 5). In 
paper III, we used LC-MS/MS to measure 8-oxo-dGs (paper III: Figure 3).  
 
3.4 Evaluation of Drug Target Interactions 
3.4.1 Gel Electrophoresis Mobility Shift Assay  
The interactions of proteins with DNA can be examined using EMSA (gel electrophoresis 
mobility shift assay). In principle, the mixture of protein with labeled DNA fragments prepared 
in an appropriate binding buffer. Then, the mixture is loaded on a polyacrylamide gel for 
electrophoresis under native conditions. After electrophoresis, migration of the mixture is 
visualized in which the protein-nucleic acid complexes principally migrate more slowly 
compared to the free oligonucleotide probes [380]. It paper III, we showed the binding of 
OGG1 to a DNA fragment containing 8-oxo-dG:dC in the presence or absence of TH5487, the 
OGG1 inhibitor (paper III: Figure 2) .  
 
3.4.2 Differential Scanning Fluorimetry 
DSF (differential scanning fluorimetry) is a method to monitor shift in Tm (melting 
temperature) of a purified protein when interacts with its ligands. DSF is based on a fact that 
the binding of the ligand increases the thermal stability (and therefore the Tm) of the 
recombinant protein. The protein with or without the ligand is mixed with an environmentally 
sensitive dye (e.g. SYPRO Orange) and the mixture is then loaded on a real-time PCR machine. 
The PCR instrument measures the fluorescent intensity of SYPRO Orange as the temperature 
gradually goes up to denature the protein. The SYPRO Orange dye emits more strongly when 
bound to hydrophobic regions of the protein, which are exposed upon protein unfolding [381]. 
Using DSF, we displayed the increased thermal stability of OGG1 in the presence of TH5487, 
conforming their interactions (paper III, Figure 2).  
 
3.4.3 Isothermal Titration Calorimetry 
ITC (isothermal titration calorimetry) is a biophysical method to measure the in-solution 
thermodynamic parameters of interactions between a purified protein and its ligand. ITC is 
based on a fact that the binding of ligands to a recombinant protein cause heat release or 
absorption in the interactive system. ITC uses hit exchange as signal to determine the ligand 
affinity (Ka) and enthalpy change (ΔH) upon binding to the protein [382]. We confirmed 
binding of MTH1 inhibitors to the protein and calculated the corresponding Ka and ΔH values 
using ITC (paper I: Extended Data Figure 3). 
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3.4.4 Hydrogen/Deuterium Exchange Mass Spectrometry 
 MS-(mass spectrometry)based measurement of H/D (hydrogen/deuterium) exchange is an 
analytical method to investigate protein dynamics during ligand binding. When a protein is 
placed in in a D2O solution, the backbone hydrogenes can be exchanged with deuterium atoms 
in the solution. Deuterium is a heavy stable isotope of hydrogen with a mass twice that of light 
hydrogen. Thus, in the presence of a ligand, establishment of interactions between the protein 
and its ligand can limit H/D exchange which can be mapped to protein residues using MS [383]. 
The peptides containing the OGG1 residues interacting with TH5487 have been identified 
using this technique (paper III: Figure 2). 
3.4.5 Cellular Thermal Shift Assay 
Thermal stability of a protein when bound to its ligand can be assessed in cells by CETSA 
(cellular thermal shift assay). The method relies on the fact that engagement of a 
ligand/compound with its target can increase the thermal stability of the protein in cells. In 
principle, cells are treated with a compound of interest and then heated to thermally denature 
proteins. The cell lysate can be subjected to WB analysis of individual proteins or MS-based 
analysis at proteome level. For high throughput assays, the protein stability can be measured 
with two antibodies using the AlphaScreen (amplified luminescent proximity homogeneous 
assay screen) technology  [384] [385]. In our studies, we showed target engagement of MTH1 
and OGG1 inhibitors in cells using CETSA (paper I: Figure 4; paper III: Figure 3).  
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4 RESULTS AND DISCUSSION 
 
4.1 Paper I: MTH1 Inhibition Eradicates Cancer by Preventing 
Sanitation of The dNTP Pool 
Depletion of MTH1 using siRNA caused reduced clonogenic survival in transformed cell lines, 
which  was associated with increased DNA damage (53BP1, pATM, pDNA-PK foci) and 
elevated incorporation of 8-oxo-dGTP and 2-OH-dATP into genomic DNA (Figure 1,2, 
Extended Data Figure 1,2). However, MTH1 appeared to be a non-essential enzyme in non-
transformed cells (e.g. VH10 and BJ-hTERT) as its loss was much less toxic (Figure 1, 
Extended Data Figure 1). Moreover, expression of the WT protein rescued survival and 
suppressed the 53BP1 foci formation in U2OS cells. In contrast, the catalytic inactive variant 
(E56A) failed to prevent the DNA damage and enhance cell viability (Figure 1), indicating the 
NOA of cancer cells to MTH1 sanitation role. Using additional MTH1 mutants D119A and 
W117Y, with hydrolytic deficiency of 2-OH-dATP and 8-oxo-dGTP respectively, it was 
shown that both of these oxidized purine nucleotides contribute to cell death (Extended Data 
Figure 2). Analysis of the DDR revealed that ATM becomes activated upon MTH1 depletion 
to mediate phosphorylation of p53 that in turn triggers cell cycle arrest (p21 induction) and 
apoptosis (c-caspase3 increase) (Figure 2, Extended Data Figure 2). Importantly, inducible 
shRNA-mediated KD of MTH1 in SW480 xenografts could effectively stop the tumor growth 
in vivo, confirming the addiction of the tumor cells to MTH1 activity (Figure 2, Extended Data 
Figure 2).  
The target evaluation was followed by a high-throughput malachite green-base screening assay 
for small molecule inhibitors of MTH1 using dGTP as a substrate. The hits were validated in 
clonogenic survival assays to identify potent cell-active compounds, named TH287 and TH588 
(Figure 4). The inhibitory functions of these compounds were validated for the specific MTH1 
substrates (8-oxo-dGTP and 2-OH-dATP) in vitro (Extended Data Figure 3). The specificity 
of these inhibitors were examined against a panel of nudix enzymes as well as other nucleotide 
hydrolyzing enzymes, demonstrating their selectivity for MTH1 inhibition (Figure 5, Extended 
Data Figure 8). Using CETSA, the inhibitors were shown to engage with MTH1 in the cell 
(Figure 4). MTH1 inhibitors exhibited selective toxicity to cancer cells by inducing DNA 
damage and increasing the accumulation of oxidized nucleotides in the genome, which was 
consistent with RNAi-mediated KD of MTH1. In contrast, MTH1 inhibitors were tolerated by 
non-transformed cells in clonogenic and viability assays, and did not cause induction of DNA 
damage (Figure 4, Extended Data Figure 5, 6). Moreover, TH650, a structurally similar but 
inactive analogue of TH588, failed to inhibit MTH1 potently in the biochemical assay, engage 
with the target in the cell, and induce DNA damage (Figure 4, Extended Data Figure 5, 6, 8). 
Above all, the growth of therapy-refractory melanoma patient-derived xenografts were 
significantly limited by TH588 treatment (Figure 4). Additional xenografts (SW480 and MCF-
7) were also used to assess the cytotoxic effects of TH588 (Extended Data Figure 4). Overall, 
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the study introduced MTH1 as a promising anti-cancer target and described the activity of 
TH588 against human tumor cells.  
In line with this study, several independent reports have shown the NOA of tumors to MTH1 
activity. MTH1 depletion inhibited tumor growth in various xenograft models [132, 133, 136] 
[135]. Moreover, loss of MTH1 induced telomere oxidation and cell death in cancer cells with 
shortened telomeres [129]. In contrast, Kettle et al. showed that siRNA-mediated KD of MTH1 
did not affect the DDR and cell viability in their experiments [386]. MTH1 depletion could not 
limit cancer cell growth in another study, but the MTH1 siRNA sequence was not provided by 
the authors [387]. On the other hand, Warpman-Berglund and coworkers have performed a 
detailed comparison of several MTH1 siRNAs and validated the previous reports showing the 
anti-tumor effect of MTH1 suppression [132].  
Apart from paper I, several attempts were made to develop specific MTH1 inhibitors.  
Huber et al. used a proteomic approach to identify cellular targets of a drug called SCH51344, 
which is a potent inhibitor of RAS transformation [388]. These authors fished MTH1 out from 
the cell lysate using an SCH51344 affinity matrix. Subsequently, they screened a library of 
kinase inhibitors and identified a chiral drug called Critozinib as a potent MTH1 inhibitor. In 
fact, S-Critozinib, not the R-enantiomer, showed an inhibitory effect on MTH1 in vitro, induced 
DNA damage and cell death in RAS mutated cancer cells. Although MTH1 overexpression 
suppressed the S-Critozinib induced SSBs formation, it could not improve cell survival. 
Importantly, the growth of SW480 xenografts were significantly restricted by  
S-Critozinib treatment [133]. Moreover, a high-throughput screen of natural products led to the 
discovery of echinacoside as an inhibitor of MTH1. Treatment of cells with echinacoside 
resulted in increased 8-oxodG accumulation, DNA damage and apoptosis [389].  
Ji and colleagues described a novel close-to-target assay in which an ARGO (ATP-linked 
chimeric nucleotide) was used to generate luminescence signal upon MTH1 reaction.  
Using ARGO, they screened a library of kinase inhibitors and identified NVP-AEW541 as a 
potent MTH1 inhibitor [390]. NVP-AEW541 is a known inhibitor of insulin-like growth 
factor-1 receptor (IGF-1R) with established antitumor activity in vivo [391].  
Petrocchi et al. adopted a structure based design approach to discover novel MTH1 inhibitors, 
leading to a sub-nanomolar MTH1 inhibitor called IACS-4759. This compound could potently 
inhibit MTH1 activity in cell lysate but did not show toxicity in a panel of cancer cell lines 
[392]. Although the authors did not provide information about target engagement of the 
compound in cells, they concluded that MTH1 inhibition by IACS-4759 is not sufficient to 
confer anti-proliferative phenotype in tumors. In addition, Kettle and coworkers developed 
three distinct chemical series of MTH1 inhibitors with high potency and verified target 
engagement in cells. However, comparison of MTH1-null SW480 cells with parental cell lines 
showed that toxicity of their compounds were not dependent on MTH1 activity [386].  
In fact, treatment of cells with these compounds did not affect genomic 8-oxodG content and 
tail moment in the modified comet assay [132]. Purine-based MTH1 inhibitors (NPD7155 and 
NPD9948) have also been described which showed less potency and cellular toxicity compared 
to TH287 and S-Critozinib. Using proteomic profiling, it was revealed that purine-based MTH1 
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inhibitors, SCH51344 and S-Critozinib had a similar mode of action to camptothecin.  
In contrast, TH287 was clustered with tubulin poisons such as nocodazole, vinblastine, and 
paclitaxel. TH287 and TH588 appeared to prevent tubulin polymerization in vitro and induced 
a G2/M block in cell cycle analysis, proposing a possible additional mechanism of action for 
these compounds [387, 393]. In an independent study, a correlation between endogenous ROS 
production and sensitivity of melanoma cells to TH588 was found, and the TH588 toxicity was 
not rescued by MTH1 overexpression [394]. Finally, Warpman-Berglund et al. described 
TH1579, an optimized analogue of TH588, as a clinical candidate that showed selectivity for 
MTH1 in thermal proteome profiling analysis. TH1579 showed anti-tumor activity in 
xenografts that was accompanied by increased genomic 8-oxodGs in tumor samples [132].  
In conclusion, further investigations are required to understand the mechanisms of action for 
the MTH1 inhibitors as well as their potential off-target effects.  
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4.2 Paper II: hMYH and hMTH1 Cooperate for Survival in Mismatch 
Repair Defective T-Cell Acute Lymphoblastic Leukemia. 
In order to investigate the interplay between MTH1 and MUTYH, these genes were silenced 
individually or simultaneously using inducible shRNA vectors. Sorting the shRNA-bearing 
cells using FACS helped to achieve efficient KD at mRNA as well as protein level (Figure 1). 
Sub-G1 populations, as a cell death marker, were measured using FC and indicated synergistic 
lethality upon concurrent depletion of both MTH1 and MUTYH (Figure 2).  
Analysis of Annexin V and cleaved caspase 3 revealed that apoptosis induced by loss of MTH1 
is dependent on MUTYH level, again confirming the protective role of MUTYH (Figure 3).  
On top of that, overexpression of the nuclear MUTYH isoform could partially attenuate the 
cell cycle arrest and cell death associated with MTH1 loss (Figure 4). Gene expression analysis 
of DNA glycosylases suggested NEIL1 down-regulation as a survival mechanism to avoid toxic 
repair intermediates when MTH1 and MUTYH are depleted together (Figure 5).  
Collectively, this study provides supportive evidence for functional cooperation between 
MTH1 and MUTYH to sustain viability in tumor cells.  
Cumulative evidence suggests a protective role for MUTYH against oxidative DNA damages. 
For instance, MUTYH loss was shown to increase the sensitivity of cells to oxidative stress 
[217-219]. Furthermore, siRNA-mediated KD of MUTYH decreased the proliferation of PC 
(pancreatic ductal adenocarcinoma) cells, which could be further reduced by induction of 
oxidative stress or treatment with chemotherapeutic drugs. MUTYH depletion impaired PC 
cell metastatic potential, and importantly limited PC tumor growth in mouse xenografts in vivo 
[395]. Consistent with these reports, Xie et al. showed that  Mutyh and Ogg1 DKO mouse 
fibroblasts were more sensitive than WT and individual KO cells to oxidative stress, strongly 
indicating the functional cooperation between these two repair proteins occurs to sustain 
viability [396]. In contrast, Sheng and coworkers proposed that Mutyh-mediated BER 
augments cell death and neurodegeneration in Ogg1-null mice and Mutyh suppression protects 
the brain against oxidative stress [397]. However, Mutyh−/− mice in an independent study, 
exhibited better learning and memory performance compared to Mutyh−/−Ogg1−/− DKO mice 
[398].  
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4.3 Paper III: Development of a Potent OGG1 Inhibitor for Cancer 
Treatment 
OGG1 overexpression protects genomic DNA from oxidative stress in cultured cells and 
impairs cancer progression in vivo [167, 169]. Therefore, we aimed to develop potent and 
selective small molecule inhibitors of OGG1 for cancer therapy. In order to screen for OGG1 
inhibitors, we established a cleavage assay using a duplex oligonucleotide with a quenched 
fluorophore (Figure 1, Supplementary Table 1). To exclude inhibitors of APEX1, a counter 
screen was carried out and subsequent chemical optimization work led to identification of 
TH5487 as a potent OGG1 inhibitor. Selectivity of TH5487 for OGG1 was compared to 
additional glycosylases as well as a panel of nucleotide processing enzymes, confirming the 
specificity of the compound (Supplementary Table 2, 3). TH5487 impairs OGG1 binding to its 
substrate in EMSA which is not due to intercalation of DNA (Figure 2, Supplementary Figure 
1). TH5487 increases the stability of the recombinant protein in a DSF assay through 
interactions with residues in the active site, which was further confirmed through (H/D) 
exchange (Figure 2). Importantly, TH5487 engages its intended target in cells, increasing the 
thermostability of OGG1 (Figure 3). This inhibitor induces oxidative DNA damage and 
reduces the nuclear mobility of OGG1-GFP, which mimics the phenotype of a mutant OGG1 
variant (K249Q) (Figure 3). Treatment with TH5487 exhibited toxicity in Jurkat A3 cells, while 
an inactive similar compound (TH2840) was well tolerated in the cells (Figure 3). The observed 
toxicity cannot be the consequence of microtubule dynamic perturbations since TH5487 does 
not affect it (Supplementary Figure 2). The compound was assessed in viability assay and 
showed toxicity across various transformed cell lines while being less toxic in non-transformed 
and Ogg1-deficent mouse fibroblasts (Figure 4). 
To compare the cellular effects of OGG1 depletion with those from TH5487 treatment,  
we established cells containing inducible OGG1-shRNA. Loss of OGG1 inhibited proliferation 
of Jurkat A3 cells with a similar trend to that of TH5487 (Figure 4). Induction of shRNA or 
TH5787 treatment similarly resulted in elevated sub-G1 population accompanied by reduced 
EdU incorporation (Figure 4). Intriguingly, prolonged S phase was observed upon OGG1 
depletion/inhibition (Figure 4). In addition, drug combination screenings revealed synergistic 
effects when TH5487 was used together with taxol or karonudib (MTH1 inhibitor) (Figure 5). 
Overall, this study describes TH5487 as a novel OGG1 inhibitor which can exemplify the 
phenotypic lethality in cancer.  
So far, two independent research teams have presented small molecule inhibitors of OGG1 
[399, 400]. However, their work is limited to biochemical assays and the compounds have not 
been examined in cell lysates or in cells. Mahajan et al. synthesized 9-alkylated-8-oxoguanines 
but the most potent compounds could inhibit OGG1 activity by approximately 30% in the 
cleavage assay, indicating lack of potency [399]. In an independent study, Donley et al. 
screened for OGG1 inhibitors using a fluorescence-based assay. They assessed the top five 
compounds in a gel-based cleavage assay and confirmed their inhibitory activity.  
However, none of the compounds disturbed the interaction of OGG1 with the specific substrate 
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in an EMSA. The major drawback of this study is the screening assay in which OGG1 was 
used as a bifunctional DNA glycosylase without adding APEX1 into the reaction mix. 
In fact, we assessed the most potent compound (O8) in APEX1 cleavage assay (Supplementary 
Figure 3). Accordingly, it was revealed that O8 prevents APEX1-mediated digestion of  
AP-site substrates, suggesting a different mechanisms of action for the compounds described 
by Donley and coworkers. 
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